<DOC>
	<DOCNO>NCT00638144</DOCNO>
	<brief_summary>End stage HCV-related cirrhosis become major indication liver transplantation ( LT ) . Unfortunately , recurrence HCV infection liver graft occur almost patient follow transplantation cause persistent infection lead chronic hepatitis cirrhosis significant proportion patient . To date effective way prevent HCV reinfection liver graft early phase transplantation . . Early passive immunotherapy neutralize antibody HCV consider prevent reinfection liver transplant patient associated HCV . This approach well establish case patient undergo liver transplantation chronic hepatitis B virus infection . Our purpose produce neutralize monoclonal antibody prevent reinfection liver graft .</brief_summary>
	<brief_title>Prevention Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified Chronically Infected Patients Patients With Resolved Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Health insurance Resolved HCV infection ( HCV RNA negative since 6 month ) HCV chronically infect ( RNA positive ) Anti HCV antibody positive Volunteers inform patient Immunosuppression HBV HIV infection Pregnancy Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>antibody mediate neutralization</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>